March 7, 2024

Expert Consensus on Diagnostic Criteria for Urticarial Vasculitis and Chronic Spontaneous Urticaria

 A recent Delphi survey facilitated the establishment of diagnostic criteria and differential diagnoses between urticarial vasculitis and chronic spontaneous urticaria patients presenting with recurring wheals.  Urticarial vasculitis (UV) is characterized by long-lasting wheals with or without angioedema and the histopathologic finding of leukocytoclastic vasculitis. Distinguishing UV from chronic spontaneous urticaria (CSU) can be challenging due...

Benralizumab in Patients With Chronic Spontaneous Urticaria

In the phase 2b ARROYO trial, although blood eosinophils were almost completely depleted, benralizumab treatment did not show any therapeutic advantage compared to a placebo for the treatment of chronic spontaneous urticaria. Chronic spontaneous urticaria (CSU) involves a complex interplay of various cell types and molecular mechanisms, with mast cells traditionally considered the primary drivers....

Systemic Microcirculatory Changes in Chronic Spontaneous Urticaria

Chronic spontaneous urticaria causes systemic microcirculatory changes, which VEGF may partly drive, according to the results of a cross-sectional, cohort study. Chronic spontaneous urticaria (CSU) is characterized by recurrent wheals and angioedema resulting from the activation of skin mast cells, often driven by autoimmunity through IgE and IgG autoantibodies. In this context, a cross-sectional, cohort...

Effects of Low-Dose Acetylsalicylic Acid in Postmenopausal Dense Breast Tissue

Low-dose acetylsalicylic acid reduces inflammatory protein levels and tissue perfusion in dense breast tissue in postmenopausal women, according to the results of a new phase II clinical trial. High mammographic density is a major risk factor for breast cancer, contributing to approximately 30% of all breast cancer. There is a lack of research regarding the...

Efficacy and Safety of Herceptin Biosimilar DRL-Trastuzumab in Metastatic Breast Cancer

DRL-Trastuzumab was found to have similar efficacy, safety, pharmacokinetics, and immunogenicity as Herceptin in HER2-positive breast cancer patients in a randomized, double-blind study. Trastuzumab, marketed under the brand name Herceptin, is a standard therapy for human epidermal growth factor receptor 2 (HER2)-positive breast cancer. The drug DRL_TZ, a potential trastuzumab biosimilar to Herceptin, was developed...

Clinical Implications of TP53 Null Mutation in High-Grade Serous Ovarian Cancers

A small cohort study found that p53 null mutations confer a particularly severe prognosis in high-grade serous ovarian cancers. Epithelial ovarian cancer is the fifth most common cause of female cancer-related mortality in the developed world. The most frequent type of epithelial ovarian cancer is high-grade serous ovarian cancer (HGSOC).  A cohort study published in...

Racial Disparities in Uterine Cancer Survival

A cohort study finds that histologic subtype is the main factor associated with survival disparities between Black and White uterine cancer patients. Survival disparities have existed between non-Hispanic Black and White uterine cancer patients for decades, with an increased likelihood of aggressive disease, recurrence, and death among Black patients.  A cohort study published in JAMA...

Health-Related Quality of Life in Patients With Gynecological Cancers

Gynecological cancer uniquely affects health-related quality of life. A 2023 literature review reports that treatment side effects such as fatigue, pain, and sexual dysfunction impact psychological well-being. Younger patients and those in advanced stages generally experience greater challenges. Tailoring treatment approaches and implementing supportive care can help improve health-related quality of life for survivors. Gynecological...

Disparities in Palliative Medicine Referrals and Interventions for Gynecologic Cancers

In a retrospective cohort study, racial disparities in the use of medications and interventions near end of life were observed among patients with advanced gynecologic cancer.  Palliative medicine improves outcomes in patients with gynecologic malignancies. Studies on palliative medicine in cancer have minimal representation from minority groups. A retrospective cohort study published in the journal...
<<
  • 1
  • 2
>>

Stay informed on the latest health disparities research, cultural sensitivity education, and how you can help improve patient outcomes.
This field is for validation purposes and should be left unchanged.